Overhead view of a doctor looking at his clipboard

Pipeline

Deep and Innovative Pipeline Addressing Immunological Disease

Product CandidatesDisease TargetsPreclinicalPhase 1Phase 2Phase 3

Reproxalap

Disease Targets: Dry Eye Disease

Type (ophthalmic solution)

Dry Eye Disease
Preclinical
Phase 1
Phase 2
Phase 3

Reproxalap

Disease Targets: Allergic Conjunctivitis

Type (ophthalmic solution)

Allergic Conjunctivitis
Preclinical
Phase 1
Phase 2
Phase 3

ADX-2191

Disease Targets: Proliferative Vitreoretinopathy

Type (intravitreal injection)

Proliferative Vitreoretinopathy
Preclinical
Phase 1
Phase 2
Phase 3

ADX-2191

Disease Targets: Primary Vitreoretinal Lymphoma

Type (intravitreal injection)

Primary Vitreoretinal Lymphoma
Preclinical
Phase 1
Phase 2
Phase 3

ADX-2191

Disease Targets: Retinitis Pigmentosa

Type (intravitreal injection)

Retinitis Pigmentosa
Preclinical
Phase 1
Phase 2
Phase 3

RASP-Inhibitor Discovery Platform

Disease Targets: Multiple Immune-Mediated Retinal and Systemic Indications

Multiple Immune-Mediated Retinal and Systemic Indications
Preclinical
Phase 1
Phase 2
Phase 3

ADX-629

Disease Targets: Ethanol Toxicity

Type (oral administration)

Ethanol Toxicity
Preclinical
Phase 1
Phase 2
Phase 3

ADX-629

Disease Targets: Chronic Cough

Type (oral administration)

Chronic Cough
Preclinical
Phase 1
Phase 2
Phase 3

ADX-629

Disease Targets: Sjögren-Larsson Syndrome

Type (oral administration)

Sjögren-Larsson Syndrome
Preclinical
Phase 1
Phase 2
Phase 3

ADX-629

Disease Targets: Minimal Change Disease

Type (oral administration)

Minimal Change Disease
Preclinical
Phase 1
Phase 2
Phase 3